Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Sato M, Enokida T, Wada A, Okano S, Tanaka H, Fujisawa T, Ueda Y, Motegi A, Shinozaki T, Takeshita N, Tanaka N, Zenda S, Matsuura K, Akimoto T, Hayashi R, Tahara M. Sato M, et al. Among authors: okano s. Int J Clin Oncol. 2023 Aug;28(8):1023-1032. doi: 10.1007/s10147-023-02351-9. Epub 2023 Jun 21. Int J Clin Oncol. 2023. PMID: 37344738
Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin.
Onaga R, Enokida T, Ito K, Ueda Y, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Takeshita N, Tanaka N, Hoshi Y, Tahara M. Onaga R, et al. Among authors: okano s. Front Oncol. 2023 Jun 15;13:1185198. doi: 10.3389/fonc.2023.1185198. eCollection 2023. Front Oncol. 2023. PMID: 37397398 Free PMC article.
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N, Enokida T, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Tanaka N, Onaga R, Hoshi Y, Sakashita S, Ishii G, Tahara M. Takeshita N, et al. Among authors: okano s. Oral Oncol. 2023 Dec;147:106615. doi: 10.1016/j.oraloncology.2023.106615. Epub 2023 Nov 4. Oral Oncol. 2023. PMID: 37931493
Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tanaka H, Enokida T, Okano S, Fujisawa T, Tanaka N, Takeshita N, Onaga R, Hoshi Y, Wada A, Sato M, Ueda Y, Tahara M. Tanaka H, et al. Among authors: okano s. Front Oncol. 2023 Nov 21;13:1221352. doi: 10.3389/fonc.2023.1221352. eCollection 2023. Front Oncol. 2023. PMID: 38074688 Free PMC article.
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.
Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T, Sato M, Wada A, Tanaka H, Takeshita N, Tanaka N, Onaga R, Kishida T, Uryu H, Sakashita S, Asakage T, Tahara M. Hoshi Y, et al. Among authors: okano s. Front Oncol. 2024 May 23;14:1379013. doi: 10.3389/fonc.2024.1379013. eCollection 2024. Front Oncol. 2024. PMID: 38846982 Free PMC article.
555 results